The Daily Toke

July 19, 2026

Intoxicating hemp products are facing legal and political crossfire across multiple states as federal policy uncertainty creates conflicting regulatory approaches. A coalition of hemp businesses filed a federal lawsuit Thursday in Missouri's U.S. District Court for the Western District, challenging a statewide ban set to take effect November 12 that would eliminate THC seltzers, hemp beverages, and other intoxicating hemp products currently sold in smoke shops, bars, and grocery stores. The lawsuit argues that Missouri's HB2641 contains "unconstitutionally vague" definitions for hemp and marijuana that would confuse businesses, law enforcement, and prosecutors alike. Craig Katz, government relations manager for MNG 2005, Inc.—parent company of 55 CBD Kratom stores nationwide—pointed directly at legislative overreach: "A lot of this stuff is kind of in the weeds. It's very difficult to understand. And when people are trying to legislate it, if they don't understand it, you come up with something like HB2641, which doesn't make a whole heck of a lot of sense." The coalition includes the Missouri Hemp Trade Association and Wisconsin-based Lifted Liquids Inc., all facing the elimination of a legal business sector.

The Missouri ban largely mirrors an upcoming federal prohibition that Congress approved last year, though the state bill includes conditional language: if Congress reverses course, Missouri would only permit intoxicating hemp products through licensed marijuana dispensaries, and if Congress delays the ban for a couple years, Missouri law would still ban all products except intoxicating beverages. 💰 MONEY MOVES Currently, unregulated intoxicating hemp products with as much as 1,000 mg of THC sell openly in Missouri's smoke shops, operating completely outside the state's licensed marijuana regulatory framework. The legislation tasks Missouri Attorney General Catherine Hanaway with enforcement, while Gov. Mike Kehoe and state health officials declined comment on pending litigation. Rep. Dave Hinman, the bill's sponsor, dismissed the lawsuit as a "Hail Mary" effort, arguing the legislation was thoroughly vetted through the House and Senate before the governor signed it.

The regulatory whiplash extends beyond Missouri. A federal district court judge in Toledo ruled recently that Ohio state officials are barred from enforcing the state's ban on hemp-derived intoxicating cannabinoids in beverages—but only for the 10 companies that filed a lawsuit and their vendors, creating a fragmented enforcement landscape. Similar hemp product bans have been debated in multiple states since 2023, with most failing to pass until this year's coordinated push. 🤔 THINK ABOUT IT Lawmakers are moving to ban a product category that has never killed anyone while alcohol—a federally legal substance that kills approximately 95,000 Americans annually—remains freely available in convenience stores. Meanwhile, at the federal level, Senate Democrats filed legislation to fully legalize marijuana under federal law as the Trump administration moves to merely reclassify it, signaling deepening divisions over cannabis policy direction even as state-level prohibition efforts accelerate.

The legal and political clash reflects genuine uncertainty about federal hemp policy and whether Congress will maintain its ban or reverse course. What remains clear is that Missouri's ban was designed to preemptively align state law with federal direction—and that the hemp industry, whose businesses operated legally under federal farm bill provisions until Congress decided otherwise, is fighting to survive in the gap between state and federal authority. The lawsuit arguments about vague definitions point to a real problem: legislators attempting to regulate a product category they may not fully understand, creating rules that could confuse enforcement or generate unintended consequences. The court will ultimately decide whether Missouri's ban survives constitutional scrutiny, but the broader pattern is visible—states are moving faster to eliminate intoxicating hemp products than courts or Congress appear to be moving toward resolution.

July 19, 2026

Cannabis stocks are surging toward a regulatory watershed as investors price in a favorable outcome from the DEA's expedited rescheduling hearing, which concludes July 15. The AdvisorShares Pure US Cannabis ETF (MSOS) has delivered a 103.7 percent one-year return as of May 31—crushing the S&P 500's 29.8 percent gain—and has climbed to its highest 2026 levels with $1.13 billion in assets under management. 💰 MONEY MOVES This momentum accelerated after President Trump's December executive order directed the attorney general to move marijuana from Schedule I to Schedule III, a process that has already reshaped the sector's economics for medical operators and opened the door to major exchange listings for the largest multistate operators.

Trulieve Cannabis, which holds roughly 30 percent of MSOS's portfolio, began trading on the NYSE under ticker TRLV on June 10 after restructuring to isolate its medical cannabis operations—a historic milestone for the U.S. cannabis industry and a direct result of April's rescheduling of FDA-approved medical marijuana products to Schedule III. The company reported Q1 2026 revenue of $287 million with a 59 percent gross margin, GAAP net income of $2 million, and adjusted EBITDA of $100 million at a 35 percent margin. CEO Kim Rivers credited the Trump administration's reclassification action as enabling growth, and Alliance Global maintains a "Buy" rating with a C$27 price target on the company. Curaleaf Holdings, which operates the largest dispensary footprint among U.S. operators across more than 20 states, completed a 1-for-3 reverse split in early June to prepare for its own potential uplisting, and both companies posted profitable Q1 results as the first quarter fully benefiting from 280E tax relief unfolded.

🚀 THIS IS COOL The removal of Internal Revenue Code Section 280E has proven transformative: cannabis operators faced effective federal tax rates in the 70 to 75 percent range because the code disallowed ordinary business deductions like wages, rent, and depreciation. For state-licensed medical operators, those deductions are now available, potentially pushing effective rates closer to the standard 21 percent corporate rate. This change alone reshaped the sector's profit profile in ways that traditional Wall Street metrics had previously obscured. On the consumer side, industry data shows 47 percent of Americans have tried cannabis, 79 percent live in a county with at least one dispensary, and adult-use cannabis is now legal in 24 states—a stark contrast to the 4 percent who had tried it when Gallup first asked the question in 1969. The U.S. cannabis industry is expected to reach nearly $47 billion in 2026, with cannabis tax revenue already hitting $25 billion, nearly double that of alcohol.

The June 29 DEA hearing will examine whether broader marijuana products, including adult-use cannabis, should move to Schedule III, with the proceeding required to conclude by July 15. That binary outcome—success or regulatory setback—carries real stakes: if broader rescheduling succeeds, the tax burden on recreational operators would ease substantially and access to banking, capital, and institutional investment would expand across the entire sector. If it fails, adult-use operators remain locked in Schedule I territory with 280E still fully in effect, forcing cost allocation complexity for dual-license multistate operators. 🤔 THINK ABOUT IT The sector is already pricing in success before the hearing concludes—a market bet that regulatory momentum will break through—which means July 15 carries more downside risk than upside surprise from current price levels.

Across the broader industry, larger operators with access to capital are consolidating distressed assets and expanding state-by-state. Curaleaf, Green Thumb Industries, and Glass House Brands all posted Q1 profits, while consumer behavior continues shifting toward lower-dose edibles (42 percent of edible consumers prefer 10 mg or less) and smoke-free cannabis-infused beverages. Technology adoption is accelerating in extraction, cultivation, and logistics, positioning the sector for efficiency gains as scale stabilizes. 💰 MONEY MOVES Cannabis added approximately $149 billion to the economy in 2025 and supports 425,002 full-time equivalent jobs, making the sector's regulatory status not just a Wall Street question but an economic one affecting wages, tax revenue, and market access across North America.

July 19, 2026

Federal hemp restrictions are set to take effect November 12, tightening the noose on a rapidly expanding industry that's built itself into a loophole of the 2018 Farm Bill. The impending ban—which redefines "hemp" to include all forms of THC under a new "total THC" standard capped at 0.4 milligrams per container—is already chilling planting decisions from Florida to North Carolina, with farmers and retailers reporting sudden market collapse before the law even takes effect. 💰 MONEY MOVES Jammie Treadwell, CEO of Treadwell Farms in Umatilla, Florida, told WLRN that seed sales have dropped from roughly 20 farmer clients annually to just six this year, with those purchasing smaller quantities than previous seasons. Herban Flow, a St. Petersburg retailer, pulls 80% of its revenue from hemp-derived THC products—all of which would become illegal in three months.

The federal redefinition is striking because it mirrors restrictions already moving through state legislatures at speed. California's AB-8, which took effect January 1, 2026, essentially bans smokable hemp and intoxicating cannabinoids while restricting full-spectrum products to licensed cannabis dispensaries. Delaware is splitting its hemp regulation into two bills that would funnel THC beverages through the state's three-tier alcohol licensing system and move edibles to marijuana retailers only. North Carolina's HB 328—adopted 37-6 by the state Senate on July 2 and scheduled for a House floor vote on July 27—uses the identical 0.4 milligram container limit and total THC calculation, effectively prohibiting roughly 95% of existing hemp products currently sold in the state. The language differs state to state, but the outcome is uniform: hemp products are being collapsed into cannabis licensing frameworks or eliminated entirely.

The timing creates a particular bind for farmers and small retailers. 🤔 THINK ABOUT IT Alcohol kills approximately 95,000 Americans per year. Prescription opioids kill roughly 16,000 annually. Cannabis has zero recorded overdose deaths in human history. Yet hemp-derived products—which contain the same compounds as legal cannabis in licensed states—are being treated as a public health emergency requiring emergency federal redefinition and state-by-state prohibition. The 0.4 milligram threshold isn't a regulatory standard; it's a near-total ban. A standard 10-milligram hemp-derived THC gummy vastly exceeds it. A typical dose of full-spectrum CBD tincture exceeds it. Products that consumers across the country have relied on for anxiety, chronic pain, and inflammation management for years are moving from legal commerce to Schedule VI controlled substance status on a single date.

The legal hemp industry positioned itself as a compromise position after federal cannabis prohibition became untenable. The 2018 Farm Bill created that loophole intentionally—hemp farmers could grow plants under 0.3% delta-9 THC, then chemically convert CBDA and other cannabinoids into intoxicating THC products that retained legal hemp classification. That workaround is now being sealed. What's striking is that the federal ban and state regulations don't distinguish between intoxicating products (delta-8, delta-10, THC-O) and therapeutic full-spectrum CBD containing trace amounts of THC—both get swept into the same prohibition. Industry advocates argue that full-spectrum products with naturally occurring trace THC have genuine wellness applications and should remain accessible; the legislation moving through Congress and state capitals treats them identically to synthetic intoxicants.

Donald Trump weighed in on April 23 via Truth Social, calling on Congress to update the law to preserve full-spectrum CBD products while restricting "products that pose Health risks." His statement suggests a possible window for amendment—separating therapeutic hemp from intoxicating products—but the federal ban proceeds absent Congressional action. The House hasn't yet voted on North Carolina's HB 328 and can still reject the Senate conference report when it reconvenes July 27. Delaware's second bill hasn't been filed yet. The legislative moment is narrow, but still open. What remains unclear is whether any state or federal lawmaker will attempt to distinguish between a zero-overdose therapeutic plant and the documented killers sitting on legal shelves in every convenience store.

July 19, 2026

Nearly 200 cannabis studies published in the first half of 2026 alone are painting an increasingly detailed picture of THC and CBD's role in pain management, neurological health, and infectious disease — while simultaneously exposing a stubborn gap between public use and scientific certainty on mental health applications.

The volume of research is staggering. One comprehensive review identified nearly 200 studies in just six months, with another tracking 250 by mid-July. The conditions being studied span chronic pain, cancer, autism, HIV-related complications, spinal cord injury, fibromyalgia, restless legs syndrome, and dementia agitation. 🚀 THIS IS COOL A clinical trial published in the Journal of Neurology found that a treatment containing 2.7 mg of THC and 2.5 mg of CBD reduced restless legs syndrome severity significantly after one and three months, with two-thirds of patients showing measurable improvement. High-dose CBD reduced neuropathic pain in spinal cord injury patients. CBD showed antipsychotic-like effects in mice comparable to newer non-dopamine-blocking psychosis medications. Inhaled medical cannabis produced five-year pain relief and major opioid reduction in chronic low back pain patients. And preliminary results from dementia research suggest THC/CBD treatments help manage agitation — a breakthrough for patients and families exhausted by behavioral challenges.

But here's where the science gets complicated: when researchers at the University of Sydney conducted the largest systematic review yet of randomized-controlled trials on cannabis and mental health — examining more than 50 clinical trials across 45 years of research — they found almost no high-quality evidence that cannabis helps with anxiety, depression, or PTSD. Those happen to be three of the most common reasons patients say they use medical cannabis. Insomnia, autism, and Tourette's syndrome showed "low quality" supporting evidence. For depression specifically, there wasn't a single randomized controlled trial available. "In the absence of evidence at this time, the routine use of medical cannabis products really should be rarely justified for the treatment of mental health disorders," Jack Wilson, who led the review, told NPR. The analysis included data from close to 2,500 patients — a solid pool — but the stark finding highlights how public adoption of cannabis has vastly outpaced rigorous clinical research in certain areas.

💰 MONEY MOVES The economic implications of legalization are becoming measurable. A study published in Finance Research Letters found that recreational marijuana legalization was associated with about 38 fewer bankruptcy filings per 100,000 residents per year across all 50 states and Washington D.C. between 2001 and 2024. Meanwhile, research out of Michigan State University found that THC and CBD may reduce inflammatory processes tied to HIV-associated neurocognitive disorders — a finding with real consequences for people managing a chronic infection. And dispensary access itself appears to reduce opioid harm; researchers found that marijuana dispensaries and legalization laws were associated with fewer nonfatal opioid poisonings, adding evidence that legal cannabis access influences how people manage pain.

The University of California Health system is investing heavily in filling these research gaps. Eighteen cannabis clinical trials are currently in progress across UC campuses, with ten open to eligible participants. Studies are examining age-dependent effects of THC on abuse liability and impairment, brain mechanisms supporting cannabis-induced pain relief, and how THC and CBD affect cognition and decision-making in people living with HIV. This is where clinical science and patient need are finally intersecting — but the funding and regulatory landscape that made these trials possible took decades to create, even in cannabis-friendly California.

🤔 THINK ABOUT IT We have rigorous evidence that cannabinoids reduce neuropathic pain, manage agitation in dementia, and appear to modulate inflammatory disease processes. We have zero recorded deaths from cannabis overdose in human history. Yet more than 50 years after Nixon's Controlled Substances Act classified cannabis as Schedule I — despite his own Shafer Commission recommending decriminalization — thousands of patients still navigate a legal and medical system that treats the plant as having no accepted medical use. The science is moving faster than the policy. The question now is whether the policy will catch up before another generation of patients has to choose between evidence-based care and the law.

July 19, 2026

Texas Hemp Market Collapses Into Legal Limbo as Appeals Court Halts Protections for Retailers

The Texas Fifteenth Court of Appeals dealt a crushing blow to the state's hemp industry on Friday, denying an emergency request to maintain a temporary injunction that had protected smokable hemp sales since May. The decision clears the way for the state's controversial "Total THC Rule"—which counts THCA as 88% Delta-9 THC—to take effect again, potentially eliminating the majority of products sold at hemp retailers across Austin and beyond. Yet even with the legal pathway reopened, the Department of State Health Services appears frozen in place. "DSHS is still determining how to proceed given that there is not a final disposition yet," agency spokesperson Lara Anton said, leaving retailers and consumers in a state of uncertainty that has defined Texas cannabis policy for the better part of two years.

The chaos traces back to March 31, 2026, when new DSHS rules rewrote how the state measures THC in hemp products. Previously, labs measured only Delta-9 THC—the psychoactive compound that must stay below 0.3% by dry weight for hemp to remain legal. THCA, which converts to Delta-9 when heated or smoked, wasn't counted. That loophole allowed Texas hemp retailers to sell smokable flower and concentrates with high THCA content, functionally creating a legal cannabis market that resembled what customers find in states where marijuana is fully legal. Within days of the new rules taking effect, most smokable hemp disappeared from shelves. The Texas Hemp Business Council, Hemp Industry & Farmers of America, and a coalition of retailers sued, arguing DSHS had overstepped its authority by redefining terms the Legislature had already established. On May 1, Travis County Judge Maya Guerra Gamble agreed and issued a temporary restraining order that put the smokable ban on ice. 💰 MONEY MOVES Small hemp retailers like MARYJAE and Hometown Hero, which had built entire business models around compliant smokable products, got their inventory back on shelves. The reprieve lasted just over a month.

🤔 THINK ABOUT IT Texas maintains some of the nation's strictest cannabis laws—recreational marijuana is flatly illegal, with possession of up to two ounces classified as a Class B misdemeanor carrying up to 180 days in jail and a $2,000 fine. Yet Austin, Texas's most cannabis-friendly city, voted overwhelmingly in 2022 to deprioritize enforcement of low-level marijuana possession. Police generally ignore small personal amounts. Meanwhile, legal hemp-derived THC products are technically allowed under federal law and Texas law—provided they stay under the 0.3% Delta-9 threshold—but the state keeps redefining what "counts" as THC in ways that make compliance nearly impossible. The result is a legal framework so tangled that even compliant businesses don't know whether they can operate tomorrow.

Governor Greg Abbott's June veto of Senate Bill 3—which would have completely banned hemp-derived products containing any THC—signaled some political will to regulate rather than destroy the industry. Abbott called for regulation instead of prohibition, and a special session was scheduled for July 21 to resolve the stalemate. But the appeals court's decision suggests that whatever regulatory framework emerges will face constant legal challenges. Lukas Gilkey, CEO of Austin-based retailer Hometown Hero, acknowledged the whiplash: "I know it's been a lot of crazy back and forth and the lawyers are doing their best to push this forward and keep this going. This is really going to impact the small stores. If they have flower that qualifies under the rules, then they're allowed to sell it. If they don't, then theoretically, yes, they would have to stop." The lawsuit continues, but the temporary injunction that allowed businesses to operate without fear is gone. Now the question is whether DSHS will actually begin enforcing the Total THC Rule—and whether the courts will ultimately side with the industry or the state.